Mode
Text Size
Log in / Sign up
N/A Completed N=102

Observational Registry of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors

Congenital Bleeding Disorder · Haemophilia A With Inhibitors · Haemophilia B With Inhibitors
Source: ClinicalTrials.gov NCT00703911 ↗
Enrolled (actual)
102
Serious AEs
0.0%
Results posted
Dec 2011
Primary outcomePrimary: Percentage of Bleed Treatments Resulting in Effective Bleed Resolution (All Bleed Episodes) — 61.7; 67.9; 62.2; 56.9 percentage of bleed episodes

Summary

This study was conducted in Africa, Europe, the Middle-East and South America. The primary objective of this registry was to observe the use of single dose and multi-dose use of activated recombinant human factor VII and to compare short-term outcomes, including effectiveness, safety, quality of life and treatment satisfaction with the approved treatments.

Outcome Measures

OutcomeResultp-value
PRIMARY
Percentage of Bleed Treatments Resulting in Effective Bleed Resolution (All Bleed Episodes)
61.7; 67.9; 62.2; 56.9 —
PRIMARY
Percentage of Bleed Treatments Resulting in Effective Bleed Resolution (Spontaneous Bleed Episodes)
59.0; 62.6; 60.4; 55.7 —
PRIMARY
Percentage of Bleed Treatments Resulting in Effective Pain Relief (All Bleed Episodes)
71.3; 82.1; 60.6; 69.7 —
PRIMARY
Percentage of Bleed Treatments Resulting in Effective Pain Relief (Spontaneous Bleed Episodes)
68.0; 79.1; 58.2; 67.1 —
SECONDARY
Percentage of Bleed Treatments Resulting in Effective Haemostasis (Cessation of Bleeds) by Time Point (All Bleed Episodes)
21.1; 16.8; 25.8; 21.5; 36.9; 32.5 —
SECONDARY
Percentage of Bleed Treatments Resulting in Effective Haemostasis (Cessation of Bleeds) by Time Point (Spontaneous Bleed Episodes)
19.3; 7.7; 24.4; 23.6; 36.9; 27.8 —
SECONDARY
Percentage of Bleed Treatments Resulting in Effective Pain Relief by Time Point (All Bleed Episodes)
27.7; 29.9; 19.8; 30.8; 53.1; 59.7 —
SECONDARY
Percentage of Bleed Treatments Resulting in Effective Pain Relief by Time Point (Spontaneous Bleed Episodes)
24.7; 24.4; 18.7; 28.8; 49.1; 55.6 —
SECONDARY
Total Number of Injections (All Bleed Episodes)
2; 2; 2; 1 —
SECONDARY
Total Number of Injections (Spontaneous Bleed Episodes)
2; 2; 2; 1 —
SECONDARY
Total Exposure (Cumulative Dose) to Activated Recombinant Human Factor VII (All Bleed Episodes)
270; 267; 256; 270 —
SECONDARY
Total Exposure (Cumulative Dose) to Activated Recombinant Human Factor VII (Spontaneous Bleed Episodes)
184; 284; 270; 270 —
SECONDARY
Percentage of Patients Reporting Satisfaction With Symptom Relief (All Bleed Episodes)
72.7; 82.1; 69.3; 67.8 —
SECONDARY
Percentage of Bleed Treatments Resulting in Patient Satisfaction With Symptom Relief (Spontaneous Bleed Episodes)
68.2; 75.0; 69.2; 63.1 —
SECONDARY
Percentage of Bleed Treatments Resulting in Patient Satisfaction With Ease of Use (All Bleed Episodes)
74.9; 84.6; 74.8; 67.8 —
SECONDARY
Percentage of Bleed Treatments Resulting in Patient Satisfaction With Ease of Use (Spontaneous Bleed Episodes)
69.1; 81.5; 69.2; 61.0 —
SECONDARY
Overall Time to Cessation of Bleed/Achievement of Haemostasis (All Bleed Episodes)
1200; 720; NA; 1200 —
SECONDARY
Overall Time to Cessation of Bleed/Achievement of Haemostasis (Spontaneous Bleed Episodes)
1200; 600; NA; 1200 —
SECONDARY
Overall Time to Cessation/Achievement of Haemostasis (Spontaneous Bleed Episodes)
600; 600; NA; 480 —
SECONDARY
Childrens' Health Related Quality of Life (Haemo-QoL): Overall Score
47.49; 54.12 —
SECONDARY
Adults' Health Related Quality of Life (Haemo-QoL-A): Overall Score
35.31; 34.46 —

Eligibility Criteria

Inclusion Criteria

  • Diagnosed with haemophilia A or B with inhibitors
  • Experience mild to moderate spontaneous bleeds which require on-demand treatment and who are currently prescribed activated recombinant human factor VII
  • Be able and willing to provide informed consent (or proxy consent by caregiver, if applicable), as required by local research ethics committee, governmental or regulatory authorities
  • Be willing to provide information on at least one alternate contact person in the event that the patient be somehow lost-to-follow-up over the course of registry participation (not applicable if patient is withdrawn)

Exclusion Criteria

  • Known hypersensitivity to the active substance or the excipients in the formulation of activated recombinant human factor VII, or to mouse, hamster or bovine protein
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00703911). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search